Cargando…

The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer’s disease

Alzheimer’s disease (AD) is a chronic neurodegenerative disease, which is associated with learning and memory impairment in the elderly. Recent studies have found that treating AD in the way of chromatin remodeling via histone acetylation is a promising therapeutic regimen. In a number of recent stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Shuang-shuang, Zhang, Rui, Wang, Gang, Zhang, Yong-fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504819/
https://www.ncbi.nlm.nih.gov/pubmed/28702178
http://dx.doi.org/10.1186/s40035-017-0089-1
_version_ 1783249355152556032
author Yang, Shuang-shuang
Zhang, Rui
Wang, Gang
Zhang, Yong-fang
author_facet Yang, Shuang-shuang
Zhang, Rui
Wang, Gang
Zhang, Yong-fang
author_sort Yang, Shuang-shuang
collection PubMed
description Alzheimer’s disease (AD) is a chronic neurodegenerative disease, which is associated with learning and memory impairment in the elderly. Recent studies have found that treating AD in the way of chromatin remodeling via histone acetylation is a promising therapeutic regimen. In a number of recent studies, inhibitors of histone deacetylase (HDACs) have been found to be a novel promising therapeutic agents for neurological disorders, particularly for AD and other neurodegenerative diseases. Although HDAC inhibitors have the ability to ameliorate cognitive impairment, successful treatments in the classic AD animal model are rarely translated into clinical trials. As for the reduction of unwanted side effects, the development of HDAC inhibitors with increased isoform selectivity or seeking other directions is a key issue that needs to be addressed. The review focused on literatures on epigenetic mechanisms in recent years, especially on histone acetylation in terms of the enhancement of specificity, efficacy and avoiding side effects for treating AD.
format Online
Article
Text
id pubmed-5504819
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-55048192017-07-12 The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer’s disease Yang, Shuang-shuang Zhang, Rui Wang, Gang Zhang, Yong-fang Transl Neurodegener Review Alzheimer’s disease (AD) is a chronic neurodegenerative disease, which is associated with learning and memory impairment in the elderly. Recent studies have found that treating AD in the way of chromatin remodeling via histone acetylation is a promising therapeutic regimen. In a number of recent studies, inhibitors of histone deacetylase (HDACs) have been found to be a novel promising therapeutic agents for neurological disorders, particularly for AD and other neurodegenerative diseases. Although HDAC inhibitors have the ability to ameliorate cognitive impairment, successful treatments in the classic AD animal model are rarely translated into clinical trials. As for the reduction of unwanted side effects, the development of HDAC inhibitors with increased isoform selectivity or seeking other directions is a key issue that needs to be addressed. The review focused on literatures on epigenetic mechanisms in recent years, especially on histone acetylation in terms of the enhancement of specificity, efficacy and avoiding side effects for treating AD. BioMed Central 2017-07-10 /pmc/articles/PMC5504819/ /pubmed/28702178 http://dx.doi.org/10.1186/s40035-017-0089-1 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Yang, Shuang-shuang
Zhang, Rui
Wang, Gang
Zhang, Yong-fang
The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer’s disease
title The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer’s disease
title_full The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer’s disease
title_fullStr The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer’s disease
title_full_unstemmed The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer’s disease
title_short The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer’s disease
title_sort development prospection of hdac inhibitors as a potential therapeutic direction in alzheimer’s disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504819/
https://www.ncbi.nlm.nih.gov/pubmed/28702178
http://dx.doi.org/10.1186/s40035-017-0089-1
work_keys_str_mv AT yangshuangshuang thedevelopmentprospectionofhdacinhibitorsasapotentialtherapeuticdirectioninalzheimersdisease
AT zhangrui thedevelopmentprospectionofhdacinhibitorsasapotentialtherapeuticdirectioninalzheimersdisease
AT wanggang thedevelopmentprospectionofhdacinhibitorsasapotentialtherapeuticdirectioninalzheimersdisease
AT zhangyongfang thedevelopmentprospectionofhdacinhibitorsasapotentialtherapeuticdirectioninalzheimersdisease
AT yangshuangshuang developmentprospectionofhdacinhibitorsasapotentialtherapeuticdirectioninalzheimersdisease
AT zhangrui developmentprospectionofhdacinhibitorsasapotentialtherapeuticdirectioninalzheimersdisease
AT wanggang developmentprospectionofhdacinhibitorsasapotentialtherapeuticdirectioninalzheimersdisease
AT zhangyongfang developmentprospectionofhdacinhibitorsasapotentialtherapeuticdirectioninalzheimersdisease